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ABSTRACT
Fibromyalgia is a form of non-articular rheumatism in which inflammatory cytokines seem to be involved. 
However, there is still no analytical specific diagnostic criterion for this disease. The aim was to examine 
a possible role of fractalkine as a biomarker in fibromyalgia. Plasma levels of soluble fractalkine were 
compared between women diagnosed with fibromyalgia (n=17) and healthy women (n=10) as controls. 
Fractalkine released by monocytes was also evaluated. Fibromyalgia patients showed lower plasma 
fractalkine than healthy women. Since most inflammatory pathologies show elevated plasma levels of 
soluble fractalkine, the results may contribute towards a differential diagnosis for fibromyalgia.
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INTRODUCTION
Fibromyalgia (FM) is a form of non-articular 
rheumatism defined as the presence of a prolonged 
history (>3 months) of chronic generalized 
musculoskeletal pain (Wolfe et al. 2010). There is 
still no specific analytical diagnostic criterion for 
this pathology. Among the posited ætiologies of FM, 
special attention has been paid to the hypothesis of 
the involvement of inflammatory cytokines (Van 
West and Maes 2001), especially IL-8 (CXCL8) 
(Ortega et al. 2009, Bote et al. 2012).
Fractalkine (CX3CL1) is a special inflamma-
tory chemokine with chemotactic activity for 
monocytes, NK cells, and T cells. It also acts as an 
adhesion molecule for leukocytes (Jones et al. 2012), 
and is a mediator of pathological pain (Milligan et 
al. 2008). Evidence has been emerging regarding 
its active role in many rheumatic diseases. These 
include rheumatoid arthritis, Sjogren's syndrome, 
systemic lupus erythematosus, and scleroderma, 
as well as other diseases associated with systemic 
inflammation in which it is always found at high 
levels (Jones et al. 2012). For this reason, the aim of 
this study was to compare plasma levels of soluble 
fractalkine in women diagnosed with fibromyalgia 
when compared with control healthy women.
The subjects of the study were 17 volunteer 
patients (all women, aged 32–60 years) diagnosed 
with FM by a rheumatologist (according to the 
American College of Rheumatology criteria for 
the syndrome) (Wolfe et al. 2010). The exclusion 
criteria were: neoplastic disorder (as determined 
from the patient's medical history); infection; 
cardiopulmonary, vascular, or other internal 
medical conditions; and oral or local corticosteroid 
or anticytokine therapy that might affect cytokine 
An Acad Bras Cienc (2014) 86 (4)
1916 JUAN J. GARCIA and EDUARDO ORTEGA
levels. FM patients were classified as belonging 
to the primary group (with no definitive organic 
factor triggering the syndrome) according to the 
classification criteria of Müller et al. (2007) – i.e., 
Group I: FM with sensitivity to pain but no diagnosis 
of depression or other relevant psychiatric disorder. 
Ten sedentary healthy women (HW), who had no 
symptoms of pain or infectious illness at the time 
of blood sampling, served as age-matched controls 
(aged 25–55 years). The levels of soluble CX3CL1 
in the plasma and in the supernatants of isolated 
(“Monocyte Isolation Kit II”, MiltenyiBiotec 
GmbH, BergischGladbach, Germany) cultured 
monocytes were determined using an enzyme-
like immunoassay (RayBio® Human Fractalkine 
ELISA Kit, RayBiotech, Norcross, USA). Statistical 
comparisons were done using the parametric 
Student's t-test. The results are presented as the mean 
(± standard error of the mean).
Figure 2 - Soluble fractalkine (CX3CL1) release by non-activated (A: spontaneous) and 
lipopolysaccharide-activated (B: LPS-induced) monocytes from healthy women (HW) and from 
fibromyalgia patients (FM). Each column represents the mean±SEM of ten experiments performed in 
duplicate (one experiment per volunteer).
Figure 1 - Plasma levels of soluble fractalkine (CX3CL1) in 
fibromyalgia patients (FM) and in healthy women (HW). The 
soluble CX3CL1 level in the FM group was 5.021 (±0.308 
SEM) ng/ml and in the HW group 8.511 (±0.563 SEM) ng/ml; 
p=0.0001, Student's t-test).
The plasma concentration of CX3CL1 in FM 
patients was lower than in the HW group (p<0.001; 
Fig. 1). However, the production of soluble fractalkine 
by isolated monocytes was not different between 
FM patients and HW (p>0.05; Fig. 2).
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To the best of our knowledge, this is the first 
study in evaluating fractalkinein fibromyalgia. 
Soluble CX3CL1 is generated by the limited 
proteolysis of ADAM (“a disintegrin and 
metallopeptidase”) metallopeptidase domain 10 
(ADAM10) and ADAM17 (also called TACE 
– tumour necrosis factor-α-converting enzyme) 
(Garton et al. 2001, Hundhausen et al. 2003). This 
appears to suggest that the lower concentration in 
the plasma of fibromyalgia patients may be due to 
a functional defect of ADAM10 and/or ADAM17. 
However, the capacity of isolated monocytes 
to produce soluble CX3CL1 was similar in the 
fibromyalgia patients and in the healthy women, so 
that, at least in monocytes, it does not seem that the 
functionality of ADAM10 and/or ADAM17 (which 
are present in monocytes) is affected in fibromyalgia. 
Although further studies are needed to clarify the 
mechanisms underlying the decrease of soluble 
CX3CL1 in the plasma from fibromyalgia patients; 
particularly differences in the affinity of fractalkine 
to its receptor CX3CR1 between FM patients and 
HW, as well as to evaluate potential changes in the 
CX3CR1 expression in FM patients.This lower 
concentration should be another differentiating 
element between this syndrome and most other 
inflammatory rheumatic diseases, in which this 
chemokine is usually increased in plasma (Jones et 
al. 2012). Then, plasma level of soluble fractalkine 
could contribute as a biomarker for the differential 
diagnosis of fibromyalgia compared with other 
inflammatory conditions.
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RESUMO
A fibromialgia é uma forma de reumatismo não articular, 
em que as citocinas inflamatórias parecem estar envolvidas. 
No entanto, ainda não há um critério de diagnóstico 
específico de análise para esta doença. O objetivo 
foi examinar um possível papel de fractalcina como um 
biomarcador para a fibromialgia. Os níveis plasmáticos de 
fractalcina solúvel foram comparados entre as mulheres 
diagnosticadas com fibromialgia (n=17) e mulheres 
saudáveis (n=10) como controle. Fractalcina liberada por 
monócitos também foi avaliada. Pacientes com fibromialgia 
mostraram níveis plasmáticos de fractalcina mais baixos 
do que mulheres saudáveis. Como a maioria das patologias 
inflamatórias apresentam níveis plasmáticos elevados de 
fractalcina solúvel, os resultados podem contribuir para um 
diagnóstico diferencial para a fibromialgia.
Palavras-chave: fractalcina, fibromialgia, biomarcador, 
quimiocina, monócito.
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